Physician profile
Richard Culbert
NPI 1881663995
$2,592.56
in general payments reported to CMS, 2019-2025
17 companies · $604 in 2025
The $604 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $190 · 2020: $74.07 · 2021: $212 · 2022: $435 · 2023: $545 · 2024: $533 · 2025: $604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,682.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,682.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $426.99 | 2022-2025 | Vabysmo |
| Abbvie INC. | $400.66 | 2022-2025 | Ozurdex |
| Allergan, INC. | $252.01 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $250.47 | 2022-2025 | Syfovre |
| Regeneron Healthcare Solutions, INC. | $229.21 | 2022-2025 | Eylea Hd, Eylea |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $204.36 | 2019-2021 | |
| Astellas Pharma US INC | $184.76 | 2023-2025 | Izervay |
| Ani Pharmaceuticals, INC. | $158.31 | 2025 | Iluvien, Yutiq |
| Coherus Oncology, INC. | $141.93 | 2023-2024 | |
| Eyepoint US, INC. | $104.84 | 2022 | |
| Harrow Eye, LLC | $74.36 | 2024 | Iheezo, Triesence |
| Alimera Sciences, INC. | $54.18 | 2023 | Iluvien |
| Bausch & Lomb Americas INC. | $40.71 | 2024-2025 | Stellaris |
| Sandoz INC. | $32.47 | 2024 | Cimerli |
| Novartis Pharmaceuticals Corporation | $19.20 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurotech Pharmaceuticals, INC. | $18.10 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Culbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.